FIGURE 2
FROM:
Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma
F Donskov, M Middleton, K Fode, P Meldgaard, W Mansoor, J Lawrance, N Thatcher, H Nellemann and H von der Maase
BACK TO ARTICLEFigure 2.
Kaplan–Meier estimates for progression-free survival of IL-2 plus histamine (—) vs IL-2 alone (- - -). (A) Aarhus, n=63, (B) Manchester, n=41.
